ARGX (ARGX) Stock Price & Analysis
ARGX (ARGX) rose 0.18% to USD 884 as of June 9, 2026 at 23:53 UTC, according to Nexqual real-time market data.
ARGX last closed at USD 882.41; the session ranged USD 870.23–898.73 on volume of 248,072 shares. Market capitalization is $55.25B, with a 52-week range of USD 510.06–934.62 (NMS). Source: Nexqual, June 9, 2026 at 23:53 UTC.
Key Statistics (as of June 9, 2026 at 23:53 UTC)
| Price | USD 884 |
|---|---|
| Change | ▲ 0.18% (up) |
| Previous Close | USD 882.41 |
| Open | USD 890.35 |
| Day Range | USD 870.23 – 898.73 |
| 52-Week Range | USD 510.06 – 934.62 |
| Volume | 248,072 shares |
| Market Cap | $55.25B |
| Exchange | NMS |
Technical Analysis (ARGX)
Nexqual's technical model rates ARGX "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 9, 2026 at 23:53 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 65.48 (neutral) |
| vs SMA50 | Above (USD 803.38) |
| MACD | 20.38 (positive) |
Analyst Ratings (ARGX)
Wall Street analysts rate ARGX "Strong Buy" based on 22 analysts, with a mean price target of USD 1,023.89 (range USD 686.19–1,282.06), per Nexqual as of June 9, 2026 at 23:53 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 22 |
| Mean Target | USD 1,023.89 |
| High Target | USD 1,282.06 |
| Low Target | USD 686.19 |
| Buy / Hold / Sell | 21 / 3 / 0 |
Earnings (ARGX)
| Next Earnings Date | 2026-07-23 |
|---|---|
| EPS Estimate | USD 5.22 |
| Revenue Estimate | $1.23B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 4.7 vs est 4.19 ▲ beat |
| 2025-12-31 | USD 6.79 vs est 5.2 ▲ beat |
| 2025-09-30 | USD 4.44 vs est 3.54 ▲ beat |
| 2025-06-30 | USD 3.26 vs est 2.61 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:53 UTC.
Financials & Fundamentals (ARGX)
| Total Revenue | $4.74B |
|---|---|
| Revenue Growth (YoY) | +62.60% |
| Gross Margin | +58.11% |
| Operating Margin | +30.01% |
| Profit Margin | +31.40% |
| Debt / Equity | 0.64 |
| Total Cash | $4.44B |
| Total Debt | $47.16M |
Source: Nexqual, June 9, 2026 at 23:53 UTC.
Financial Health Score (ARGX)
Nexqual rates ARGX's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 23:53 UTC.
| Growth | Strong — Revenue +68% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 58%, operating 30% |
| Balance Sheet | Strong — $4.44B cash vs $47M debt, net cash position |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (ARGX)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +47.49% |
| Shares Outstanding | 62.19M |
| Float | 1.55B |
| Short % of Float | +3.46% |
Source: Nexqual, June 9, 2026 at 23:53 UTC.
Leadership (ARGX)
ARGX is led by Karen Massey (age 46), CEO & Executive Director, per Nexqual as of June 9, 2026 at 23:53 UTC.
| CEO & Executive Director | Karen Massey (age 46) |
|---|---|
| Co-Founder & Non-Executive Chairman of the Board | Timothy Van Hauwermeiren EMBA, M.Sc. (age 53) |
| Chief Financial Officer | Karl Gubitz (age 55) |
| Chief Scientific Officer | Peter Ulrichts (age 45) |
| Vice President of Corporate Development & Strategy | Arjen Lemmen M.Sc. (age 40) |
Major Backers & Investors (ARGX)
Notable institutional backers of ARGX include FMR, LLC, Price (T.Rowe) Associates Inc, Janus Henderson Group PLC, according to Nexqual as of June 9, 2026 at 23:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 8.03% |
| Price (T.Rowe) Associates Inc | 5.43% |
| Janus Henderson Group PLC | 4.09% |
| Capital Group | 3.63% |
| Artisan Partners Limited Partnership | 2.36% |
| EuroPacific Growth Fund-EUPAC Fund | 1.76% |
| Fidelity | 1.75% |
| Wellington Management | 1.64% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 2.56% |
Source: Nexqual, June 9, 2026 at 23:53 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ASND | Ascendis Pharma A/S | USD 213.23 | ▲ 1.32% |
| KRYS | Krystal Biotech, Inc. | USD 309.75 | ▲ 2.91% |
| GMAB | Genmab A/S | USD 25.1 | ▼ 0.2% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 297.69 | ▼ 1.77% |
| LKFT | Lakefront Biotherapeutics | USD 28.27 | ▲ 0.89% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:53 UTC. This page is informational and not investment advice.